Daily Dose: Subclinical CVD Affects 1 in 3 US Adults with Diabetes
Your daily dose of clinical news you may have missed.
Pfizer Wins FDA Approval for Vaccine against RSV in Older Adults
The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.
Long COVID was Apparent by Summer 2020 and in a Wide Range of Patients
Symptoms of long COVID were apparent by the summer of 2020, said physiatrist Dr Leslie Rydberg, coauthor of new consensus guidelines on management of neurologic sequelae.
One in 3 US Adults with T2D Shows Evidence of Subclinical CVD Based on Cardiac Biomarkers
As indicated by levels of 2 common biomarkers of cardiac injury, 33.4% of US adults with T2D showed evidence of undetected CVD vs only 16.1% of those without T2D.
Landmark NIH Study: Symptom-based Scoring System May Help Diagnose Long COVID
Researchers found a total of 12 symptoms that contributed to the long COVID scoring system.
Daily Dose: Disparities in Diabetes Care
FDA Approves First Oral Antiviral Medication for COVID-19 Treatment among Adults
The FDA approved Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease.
FDA Approves SGLT-2/1 Inhibitor Sotagliflozin, Grants Broad Heart Failure Indication
The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.
Comorbidities Associated with COPD Affect Outcomes, Require Attention
At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.
Daily Dose: Weight Management in Primary Care
New Study Highlights Disparities in Diabetes Care between Urban, Rural Patients
New study found that patients living in urban areas were more likely to meet all aspects of key metrics of diabetes care.
Robust RSV Surveillance Data Will be Key to Getting US Clinicians Comfortable with New Adult Vaccine
Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.
Daily Dose: FDA Approves Buprenorphine Extended-release Injection for Opioid Use Disorder
Social Media is a Mental Health Hazard for Nation's Youth, Surgeon General Says
The AAFP and other national medical groups endorsed the warning from Surgeon General Murthy that social media is fueling the mental health crisis among young Americans.
Chronic Pain in America: Who is at Greatest Risk?
A recent CDC report showed that approximately 20% of Americans experienced chronic pain in 2021 and certain groups were most vulnerable. Details in our new slideshow.
Are US Seniors Ready for an RSV Vaccine? Consider the Lessons of COVID-19, says Dr Kelly Moore
Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.
Daily Dose: Migraine without Aura Raises Stroke Risk for Women on Combined Hormonal Contraceptives
FDA Approves Rx Nalmefene Nasal Spray to Reverse Opioid Overdose
In a unique pharmacodynamic study, nalmefene demonstrated rapid reversal of respiratory depression from the synthetic opioid remifentanil and sustained duration of action.
GSK Adult RSV Vaccine: Expert Highlights Path to FDA Approval
Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.
Weight Loss of 15% with Oral Semaglutide 50 mg Equal to SQ Wegovy: Late Stage Clinical Trial
Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.
.jpeg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "FDA Approves First Oral Antiviral Medication for COVID-19 Treatment among Adults")
